View Older Stories View More Recent Stories

Feb 26, 2019 07:00AM Acerus to Report 2018 Financial Results and Host Investor Call
Jan 25, 2019 07:00AM Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor™ Application
Jan 11, 2019 06:00PM Acerus Announces Reporting of Anticipated Shortage of ESTRACE®
Dec 11, 2018 07:00AM Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Nov 26, 2018 07:00AM Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
Nov 6, 2018 07:00AM Acerus Reports Third Quarter 2018 Financial Results
Oct 31, 2018 07:00AM Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
Oct 30, 2018 05:00PM Acerus to Report Third Quarter 2018 Financial Results and Host Investor Call
Oct 30, 2018 08:00AM Acerus Announces Executive Leadership Changes in Corporate Finance
Oct 24, 2018 05:00PM Acerus Announces Initiation of a Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Oct 12, 2018 09:00AM Acerus Announces Closing of US$11 Million Term Loan Credit Facility
Sep 17, 2018 07:00AM Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study
Aug 13, 2018 07:00AM Acerus Reports Second Quarter 2018 Financial Results
Aug 3, 2018 07:00AM Acerus to Report Second Quarter 2018 Financial Results and Host Investor Call
Jun 28, 2018 04:51PM Acerus Announces Voting Results for the 2018 Annual and Special Meeting
Jun 14, 2018 07:00AM Acerus Announces Approval of NATESTO® in South Korea
Jun 5, 2018 09:30PM Acerus Announces Resignation of Director
May 29, 2018 07:00AM Acerus Acquires Canadian Rights to Novel Pain Relief Product for Gynecological Procedures from Pharmanest
May 17, 2018 07:00AM Acerus Announces Buyout of All Obligations under the Mattern License Agreement
May 15, 2018 07:00AM Acerus Reports First Quarter 2018 Financial Results
May 8, 2018 04:30PM Acerus to Report First Quarter 2018 Financial Results and Host Investor Call
Apr 23, 2018 07:00AM Acerus Secures Additional CDN $2M under the Quantius Loan Facility
Apr 18, 2018 07:00AM Acerus to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
Apr 13, 2018 07:00AM Acerus Announces Licensing of NATESTO® in 19 Central and Latin American Countries
Apr 10, 2018 07:00AM Acerus Announces Settlement of Melnyk Litigation
Apr 9, 2018 07:00AM Acerus Announces Launch of URIVARX® in Canada
Apr 5, 2018 04:30PM Acerus to Present at the Next CHINABIO® Partnering Forum
Mar 29, 2018 08:30AM Acerus Announces Executive Leadership Change
Mar 28, 2018 07:00AM Acerus Expands its Urology Franchise by Acquiring Canadian Rights to Stendra® from Metuchen Pharmaceuticals
Mar 21, 2018 06:00AM Acerus Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 14, 2018 05:30PM Acerus to Report 2017 Financial Results and Host Investor Call
Mar 2, 2018 07:00AM Acerus Comments on Decision Regarding Litigation
Feb 1, 2018 09:00PM Acerus Pharma’s NATESTO® to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4 2017
Jan 8, 2018 06:00AM Acerus Enters into a Licensing Agreement with Innovus to Commercialize UriVarx® in Canada
Jan 8, 2018 06:00AM Innovus Pharma Enters Into License and Distribution Agreement with Acerus Pharmaceuticals for the Commercialization of UriVarx® in Canada
Dec 24, 2017 09:00AM Acerus Receives Notice of Deficiency from Health Canada for Gynoflor™
Dec 20, 2017 07:00AM Acerus Enters into a Licensing Agreement with Viramal to Commercialize the Elegant™ Franchise in Canada
Dec 7, 2017 07:30AM Acerus Appoints Mr. Mark Lievonen to its Board of Directors
Dec 6, 2017 07:30AM Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives
Nov 30, 2017 07:00AM Acerus Secures CDN$1.6 Million of New NATESTO® Orders from Its U.S. Licensee Aytu Bioscience
Nov 23, 2017 07:00AM Acerus Announces Licensing Of NATESTO® In Brazil
Nov 7, 2017 07:00AM Acerus Reports Third Quarter 2017 Financial Results
Oct 31, 2017 07:00AM Acerus to Report Third Quarter 2017 Financial Results and Host Investor Call
Oct 17, 2017 07:00AM Acerus Announces Licensing of NATESTO® in South East Asian Countries
Aug 11, 2017 07:00AM Acerus Reports Second Quarter 2017 Financial Results
Aug 4, 2017 07:00AM Acerus to Report Second Quarter 2017 Financial Results and Host Investor Call
Jun 22, 2017 05:00PM Acerus Announces Voting Results for the 2017 Annual General Meeting
Jun 14, 2017 05:00PM Acerus Announces Licensing of NATESTO® in Major European Countries
Jun 13, 2017 05:00PM Acerus Announces Support of New Men’s Health Guidelines
Jun 5, 2017 07:30AM Acerus Announces NATESTO® License Agreement with Therios Healthcare
View More Recent Stories View Older Stories